Drug Trial Radar · NCT00199394
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Nov 2004
Primary completion
Oct 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Hakko Kirin UK, Ltd.
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.
Conditions
- Parkinson's Disease
Interventions
Istradefylline (KW-6002)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- OFF time assessed by patient diaries at endpoint.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyowa Hakko UK Ltd.
Slough, Berkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.